PTC\SB\08x (08-03)
Approved for use through 07/31/0006 ONE 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

	Application Number	10527249	
NEODIATION DIOCI COURT	Filing Date	2005-03-09	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dan)Z	
(Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Number	415/15	

		Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6290309		2001-05-29	HAYASHI	
	2	5916145		1999-06-29	СНИ	
	3	5714694		1998-05-05	WILK	
	4	5419310		1995-05-30	FRASSICA	
	5	5626607		1997-05-06	MALECKI	
	6	4655673		1987-04-07	HAWKES	
	7	4444462		1984-04-24	ONO	
	8	5372124		1994-12-13	ТАКАУАМА	

| Application Number | 10027249 | Filing Date | 2005-03-09 | Filing Date |

	9	6241740		2001-0	6-05	DAVIS				
If you wish to add additional U.S. Patent citation information please click the Add button.										
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Cite No Publication Number Kind Codes Date of cited Document Progress Appear or Reference For Publication Number Codes Date of cited Document Progress Appear Or Reference For Publication Number Number Codes Date of Cited Document Progress Appear Or Reference For Publication Number Number Codes Date of Cited Document Progress Appear Or Reference For Publication Number Number Number Codes Date of Cited Document Progress Appear Or Reference For Publication Number Numb										
	1									
If you wis	h to a	dd additional U.S. Publ	shed Ap	plication	n citation	n information p	lease click the Ad	d butto	n. Add	
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	e Foreign Document Country Kind Publication Name of Patentee of where Relevant					Passages or Relev	т.		
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examinor Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.								n T5		
1										
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner Signature Date Considered										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

(Not for submission under 37 CFR 1.99) Art Unit Examiner Name				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examiner Name		Application Number		10527249
STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99) Examiner Name STATEMENT BY APPLICANT LURING HIGH LURING HI	INFORMATION DIGGI COURT	Filing Date		2005-03-09
(Not for submission under 37 CFR 1.99) Art Unit Examiner Name	STATEMENT BY APPLICANT	First Named Inventor	Dan (DZ
Examiner Name		Art Unit		
Attorney Docket Number 415/15		Examiner Name		
Auditory Document Tellinosis 1910 10		Attorney Docket Number	er .	415/15

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. * *Projectioned projection pr

Application Number 1052749 Filing Date 2005-03-09 First Named Inventor Dan OZ Art Unit Examiner Name

Attorney Docket Number 4

415/15

10000 000 01	 and the to make the appropriate consecution.	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(vic).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

.7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Sean Liam Kelleher/	Date (YYYY-MM-DD)	2006-10-12
Name/Print	Sean Kelleher	Registration Number	54212

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bast 1450, Alexandria, V.32.11.450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.